Hepatotoxic effects of methotrexate

Evan M. Hersh, Vernon G. Wong, Edward S. Henderson, Emil J. Freireich

Research output: Contribution to journalArticle

99 Scopus citations

Abstract

Hepatotoxicity of methotrexate (MTX) therapy was studied in 22 patients. During intensive MTX therapy, values for SGOT, SGPT, LDH and BSP were 140 μ, 315 μ, 753 μ and 13% with control values of 13.5 μ, 20.5 μ, 379 μ and 4%, respectively. During intermittent therapy these values were 50 μ, 110 μ, 544 μ and 10% with controls of 13 μ, 15 μ, 355 μ and 3%. Other liver function tests remained normal. After cessation of intermittent therapy, recovery occurred in one month. Liver biopsies revealed a chronic portal inflammatory reaction in 7/10. Methotrexate can be used in nonmalignant disorders provided that careful control of its toxic side effects is maintained.

Original languageEnglish (US)
Pages (from-to)600-606
Number of pages7
JournalCancer
Volume19
Issue number4
DOIs
StatePublished - Apr 1966

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this